论文部分内容阅读
目的:探讨分析肝硬化患者血清载脂蛋白A1含量变化及意义。方法:选取我院2013年9月~2014年9月收治的84例肝硬化患者,将其分为肝硬化组(42例)和对照组(42例),测定两组患者的血清载脂蛋白A1和载脂蛋白B与其他相关指标水平。结果:经测定,肝硬化A1为0.81±0.54,对照组为1.36±0.61。观察组载脂蛋白B为0.55±0.23,对照组为0.82±0.13。观察组Chol为0.30±0.21,对照组为4.42±0.63。观察组TG为0.94±0.41,对照组1.16±0.26,观察组胆红素为36.71±29.08,对照组为8.84±5.86,观察组清蛋白为31.08±5.73,对照组为42.77±5.22.,组间对比有意义(P<0.05)。A1水平与血清胆红素的浓度呈正相关(P<0.05),与清蛋白浓度降低呈正相关(P<0.05),但Chol、apo B、TG与清蛋白、胆红素之间无任何关联(P>0.05)。结论:血清载脂蛋白A1含量变化可作为评断肝硬化患者病情严重程度的重要指标,同时还可作为评价肝脏合成功能的关键指标,对后续治疗和预后有一定的临床意义。
Objective: To investigate the changes of serum apolipoprotein A1 in cirrhotic patients and its significance. Methods: Eighty-four patients with cirrhosis who were admitted to our hospital from September 2013 to September 2014 were divided into two groups: the cirrhosis group (42 cases) and the control group (42 cases). Serum apolipoproteins A1 and apolipoprotein B with other related indicators. Results: It was determined that the cirrhosis A1 was 0.81 ± 0.54 and the control was 1.36 ± 0.61. The observation group apolipoprotein B was 0.55 ± 0.23, the control group was 0.82 ± 0.13. The observation group Chol 0.30 ± 0.21, the control group was 4.42 ± 0.63. The observation group TG 0.94 ± 0.41, the control group 1.16 ± 0.26, the observation group bilirubin 36.71 ± 29.08, the control group was 8.84 ± 5.86, the observation group albumin was 31.08 ± 5.73, the control group was 42.77 ± 5.22. Comparison made significant (P <0.05). A1 was positively correlated with serum bilirubin concentration (P <0.05) and positively correlated with decreased albumin concentration (P <0.05), but no correlation was found between Chol, apo B, TG and albumin and bilirubin P> 0.05). Conclusion: The change of serum apolipoprotein A1 level can be used as an important index to evaluate the severity of liver cirrhosis patients. It can also be used as a key index to evaluate the hepatic function and has certain clinical significance for the subsequent treatment and prognosis.